Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Sandborn

Showing results (161-170 of 186) with videos related to

Pageof 19
Sort By:
Alimentary Pharmacology & Therapeutics|September 25, 2015
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's diseaseB G Feagan, W J Sandborn, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2018
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapyW J Sandborn, P Rutgeerts, C Gasink, et al.
Alimentary Pharmacology & Therapeutics|August 1, 1997
Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot studyW J Sandborn, W J Tremaine, J A Leighton, et al.
Alimentary Pharmacology & Therapeutics|April 3, 2014
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's diseaseB G Levesque, G R Greenberg, G Zou, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2005
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's diseaseB G Feagan, W J Sandborn, J P Baker, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitisJ-F Colombel, W J Sandborn, W Reinisch, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2014
Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitisB S Boland, D L Boyle, W J Sandborn, et al.
Inflammatory Bowel Diseases|March 16, 2012
Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experienceS V Kane, S Horst, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
Inflammatory Bowel Diseases|August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.
Pageof 19

Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
Alimentary Pharmacology & Therapeutics|September 25, 2015
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's diseaseB G Feagan, W J Sandborn, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2018
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapyW J Sandborn, P Rutgeerts, C Gasink, et al.
Alimentary Pharmacology & Therapeutics|August 1, 1997
Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot studyW J Sandborn, W J Tremaine, J A Leighton, et al.
Alimentary Pharmacology & Therapeutics|April 3, 2014
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's diseaseB G Levesque, G R Greenberg, G Zou, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2005
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's diseaseB G Feagan, W J Sandborn, J P Baker, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitisJ-F Colombel, W J Sandborn, W Reinisch, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2014
Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitisB S Boland, D L Boyle, W J Sandborn, et al.
Inflammatory Bowel Diseases|March 16, 2012
Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experienceS V Kane, S Horst, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
Inflammatory Bowel Diseases|August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.
Pageof 19